1 Pulmonary Embolism Drug Market Overview 1.1 Product Overview and Scope of Pulmonary Embolism Drug 1.2 Pulmonary Embolism Drug Segment by Type 1.2.1 Global Pulmonary Embolism Drug Market Value Comparison by Type (2023-2029) 1.2.2 DS-9231 1.2.3 DS-1040 1.2.4 TRX-1 1.2.5 Others 1.3 Pulmonary Embolism Drug Segment by Application 1.3.1 Global Pulmonary Embolism Drug Market Value by Application: (2023-2029) 1.3.2 Hospital 1.3.3 Clinic 1.3.4 Others 1.4 Global Pulmonary Embolism Drug Market Size Estimates and Forecasts 1.4.1 Global Pulmonary Embolism Drug Revenue 2018-2029 1.4.2 Global Pulmonary Embolism Drug Sales 2018-2029 1.4.3 Global Pulmonary Embolism Drug Market Average Price (2018-2029) 1.5 Assumptions and Limitations 2 Pulmonary Embolism Drug Market Competition by Manufacturers 2.1 Global Pulmonary Embolism Drug Sales Market Share by Manufacturers (2018-2023) 2.2 Global Pulmonary Embolism Drug Revenue Market Share by Manufacturers (2018-2023) 2.3 Global Pulmonary Embolism Drug Average Price by Manufacturers (2018-2023) 2.4 Global Pulmonary Embolism Drug Industry Ranking 2021 VS 2022 VS 2023 2.5 Global Key Manufacturers of Pulmonary Embolism Drug, Manufacturing Sites & Headquarters 2.6 Global Key Manufacturers of Pulmonary Embolism Drug, Product Type & Application 2.7 Pulmonary Embolism Drug Market Competitive Situation and Trends 2.7.1 Pulmonary Embolism Drug Market Concentration Rate 2.7.2 The Global Top 5 and Top 10 Largest Pulmonary Embolism Drug Players Market Share by Revenue 2.7.3 Global Pulmonary Embolism Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.8 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Pulmonary Embolism Drug Retrospective Market Scenario by Region 3.1 Global Pulmonary Embolism Drug Market Size by Region: 2018 Versus 2022 Versus 2029 3.2 Global Pulmonary Embolism Drug Global Pulmonary Embolism Drug Sales by Region: 2018-2029 3.2.1 Global Pulmonary Embolism Drug Sales by Region: 2018-2023 3.2.2 Global Pulmonary Embolism Drug Sales by Region: 2024-2029 3.3 Global Pulmonary Embolism Drug Global Pulmonary Embolism Drug Revenue by Region: 2018-2029 3.3.1 Global Pulmonary Embolism Drug Revenue by Region: 2018-2023 3.3.2 Global Pulmonary Embolism Drug Revenue by Region: 2024-2029 3.4 North America Pulmonary Embolism Drug Market Facts & Figures by Country 3.4.1 North America Pulmonary Embolism Drug Market Size by Country: 2018 VS 2022 VS 2029 3.4.2 North America Pulmonary Embolism Drug Sales by Country (2018-2029) 3.4.3 North America Pulmonary Embolism Drug Revenue by Country (2018-2029) 3.4.4 U.S. 3.4.5 Canada 3.5 Europe Pulmonary Embolism Drug Market Facts & Figures by Country 3.5.1 Europe Pulmonary Embolism Drug Market Size by Country: 2018 VS 2022 VS 2029 3.5.2 Europe Pulmonary Embolism Drug Sales by Country (2018-2029) 3.5.3 Europe Pulmonary Embolism Drug Revenue by Country (2018-2029) 3.5.4 Germany 3.5.5 France 3.5.6 U.K. 3.5.7 Italy 3.5.8 Russia 3.6 Asia Pacific Pulmonary Embolism Drug Market Facts & Figures by Country 3.6.1 Asia Pacific Pulmonary Embolism Drug Market Size by Country: 2018 VS 2022 VS 2029 3.6.2 Asia Pacific Pulmonary Embolism Drug Sales by Country (2018-2029) 3.6.3 Asia Pacific Pulmonary Embolism Drug Revenue by Country (2018-2029) 3.6.4 China 3.6.5 Japan 3.6.6 South Korea 3.6.7 India 3.6.8 Australia 3.6.9 Taiwan 3.6.10 Indonesia 3.6.11 Thailand 3.6.12 Malaysia 3.6.13 Philippines 3.7 Latin America Pulmonary Embolism Drug Market Facts & Figures by Country 3.7.1 Latin America Pulmonary Embolism Drug Market Size by Country: 2018 VS 2022 VS 2029 3.7.2 Latin America Pulmonary Embolism Drug Sales by Country (2018-2029) 3.7.3 Latin America Pulmonary Embolism Drug Revenue by Country (2018-2029) 3.7.4 Mexico 3.7.5 Brazil 3.7.6 Argentina 3.8 Middle East and Africa Pulmonary Embolism Drug Market Facts & Figures by Country 3.8.1 Middle East and Africa Pulmonary Embolism Drug Market Size by Country: 2018 VS 2022 VS 2029 3.8.2 Middle East and Africa Pulmonary Embolism Drug Sales by Country (2018-2029) 3.8.3 Middle East and Africa Pulmonary Embolism Drug Revenue by Country (2018-2029) 3.8.4 Turkey 3.8.5 Saudi Arabia 3.8.6 U.A.E 4 Segment by Type 4.1 Global Pulmonary Embolism Drug Sales by Type (2018-2029) 4.1.1 Global Pulmonary Embolism Drug Sales by Type (2018-2023) 4.1.2 Global Pulmonary Embolism Drug Sales by Type (2024-2029) 4.1.3 Global Pulmonary Embolism Drug Sales Market Share by Type (2018-2029) 4.2 Global Pulmonary Embolism Drug Revenue by Type (2018-2029) 4.2.1 Global Pulmonary Embolism Drug Revenue by Type (2018-2023) 4.2.2 Global Pulmonary Embolism Drug Revenue by Type (2024-2029) 4.2.3 Global Pulmonary Embolism Drug Revenue Market Share by Type (2018-2029) 4.3 Global Pulmonary Embolism Drug Price by Type (2018-2029) 5 Segment by Application 5.1 Global Pulmonary Embolism Drug Sales by Application (2018-2029) 5.1.1 Global Pulmonary Embolism Drug Sales by Application (2018-2023) 5.1.2 Global Pulmonary Embolism Drug Sales by Application (2024-2029) 5.1.3 Global Pulmonary Embolism Drug Sales Market Share by Application (2018-2029) 5.2 Global Pulmonary Embolism Drug Revenue by Application (2018-2029) 5.2.1 Global Pulmonary Embolism Drug Revenue by Application (2018-2023) 5.2.2 Global Pulmonary Embolism Drug Revenue by Application (2024-2029) 5.2.3 Global Pulmonary Embolism Drug Revenue Market Share by Application (2018-2029) 5.3 Global Pulmonary Embolism Drug Price by Application (2018-2029) 6 Key Companies Profiled 6.1 Accu-Break Pharmaceuticals, Inc. 6.1.1 Accu-Break Pharmaceuticals, Inc. Corporation Information 6.1.2 Accu-Break Pharmaceuticals, Inc. Description and Business Overview 6.1.3 Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2018-2023) 6.1.4 Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Product Portfolio 6.1.5 Accu-Break Pharmaceuticals, Inc. Recent Developments/Updates 6.2 Dong-A Socio Holdings Co. Ltd. 6.2.1 Dong-A Socio Holdings Co. Ltd. Corporation Information 6.2.2 Dong-A Socio Holdings Co. Ltd. Description and Business Overview 6.2.3 Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2018-2023) 6.2.4 Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Product Portfolio 6.2.5 Dong-A Socio Holdings Co. Ltd. Recent Developments/Updates 6.3 F. Hoffmann-La Roche Ltd. 6.3.1 F. Hoffmann-La Roche Ltd. Corporation Information 6.3.2 F. Hoffmann-La Roche Ltd. Description and Business Overview 6.3.3 F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2018-2023) 6.3.4 F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Product Portfolio 6.3.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates 6.4 Genentech, Inc. 6.4.1 Genentech, Inc. Corporation Information 6.4.2 Genentech, Inc. Description and Business Overview 6.4.3 Genentech, Inc. Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2018-2023) 6.4.4 Genentech, Inc. Pulmonary Embolism Drug Product Portfolio 6.4.5 Genentech, Inc. Recent Developments/Updates 6.5 Verseon Corp 6.5.1 Verseon Corp Corporation Information 6.5.2 Verseon Corp Description and Business Overview 6.5.3 Verseon Corp Pulmonary Embolism Drug Sales, Revenue and Gross Margin (2018-2023) 6.5.4 Verseon Corp Pulmonary Embolism Drug Product Portfolio 6.5.5 Verseon Corp Recent Developments/Updates 7 Industry Chain and Sales Channels Analysis 7.1 Pulmonary Embolism Drug Industry Chain Analysis 7.2 Pulmonary Embolism Drug Key Raw Materials 7.2.1 Key Raw Materials 7.2.2 Raw Materials Key Suppliers 7.3 Pulmonary Embolism Drug Production Mode & Process 7.4 Pulmonary Embolism Drug Sales and Marketing 7.4.1 Pulmonary Embolism Drug Sales Channels 7.4.2 Pulmonary Embolism Drug Distributors 7.5 Pulmonary Embolism Drug Customers 8 Pulmonary Embolism Drug Market Dynamics 8.1 Pulmonary Embolism Drug Industry Trends 8.2 Pulmonary Embolism Drug Market Drivers 8.3 Pulmonary Embolism Drug Market Challenges 8.4 Pulmonary Embolism Drug Market Restraints 9 Research Finding and Conclusion 10 Methodology and Data Source 10.1 Methodology/Research Approach 10.1.1 Research Programs/Design 10.1.2 Market Size Estimation 10.1.3 Market Breakdown and Data Triangulation 10.2 Data Source 10.2.1 Secondary Sources 10.2.2 Primary Sources 10.3 Author List 10.4 Disclaimer

List of Tables Table 1. Global Pulmonary Embolism Drug Market Value Comparison by Type (2023-2029) & (US$ Million) Table 2. Global Pulmonary Embolism Drug Market Value Comparison by Application (2023-2029) & (US$ Million) Table 3. Global Pulmonary Embolism Drug Market Competitive Situation by Manufacturers in 2022 Table 4. Global Pulmonary Embolism Drug Sales (K Pcs) of Key Manufacturers (2018-2023) Table 5. Global Pulmonary Embolism Drug Sales Market Share by Manufacturers (2018-2023) Table 6. Global Pulmonary Embolism Drug Revenue (US$ Million) by Manufacturers (2018-2023) Table 7. Global Pulmonary Embolism Drug Revenue Share by Manufacturers (2018-2023) Table 8. Global Market Pulmonary Embolism Drug Average Price (USD/Pcs) of Key Manufacturers (2018-2023) Table 9. Global Key Players of Pulmonary Embolism Drug, Industry Ranking, 2021 VS 2022 VS 2023 Table 10. Global Key Manufacturers of Pulmonary Embolism Drug, Manufacturing Sites & Headquarters Table 11. Global Key Manufacturers of Pulmonary Embolism Drug, Product Type & Application Table 12. Global Key Manufacturers of Pulmonary Embolism Drug, Date of Enter into This Industry Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 14. Global Pulmonary Embolism Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Embolism Drug as of 2022) Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans Table 16. Global Pulmonary Embolism Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029 Table 17. Global Pulmonary Embolism Drug Sales by Region (2018-2023) & (K Pcs) Table 18. Global Pulmonary Embolism Drug Sales Market Share by Region (2018-2023) Table 19. Global Pulmonary Embolism Drug Sales by Region (2024-2029) & (K Pcs) Table 20. Global Pulmonary Embolism Drug Sales Market Share by Region (2024-2029) Table 21. Global Pulmonary Embolism Drug Revenue by Region (2018-2023) & (US$ Million) Table 22. Global Pulmonary Embolism Drug Revenue Market Share by Region (2018-2023) Table 23. Global Pulmonary Embolism Drug Revenue by Region (2024-2029) & (US$ Million) Table 24. Global Pulmonary Embolism Drug Revenue Market Share by Region (2024-2029) Table 25. North America Pulmonary Embolism Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 26. North America Pulmonary Embolism Drug Sales by Country (2018-2023) & (K Pcs) Table 27. North America Pulmonary Embolism Drug Sales by Country (2024-2029) & (K Pcs) Table 28. North America Pulmonary Embolism Drug Revenue by Country (2018-2023) & (US$ Million) Table 29. North America Pulmonary Embolism Drug Revenue by Country (2024-2029) & (US$ Million) Table 30. Europe Pulmonary Embolism Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 31. Europe Pulmonary Embolism Drug Sales by Country (2018-2023) & (K Pcs) Table 32. Europe Pulmonary Embolism Drug Sales by Country (2024-2029) & (K Pcs) Table 33. Europe Pulmonary Embolism Drug Revenue by Country (2018-2023) & (US$ Million) Table 34. Europe Pulmonary Embolism Drug Revenue by Country (2024-2029) & (US$ Million) Table 35. Asia Pacific Pulmonary Embolism Drug Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million) Table 36. Asia Pacific Pulmonary Embolism Drug Sales by Region (2018-2023) & (K Pcs) Table 37. Asia Pacific Pulmonary Embolism Drug Sales by Region (2024-2029) & (K Pcs) Table 38. Asia Pacific Pulmonary Embolism Drug Revenue by Region (2018-2023) & (US$ Million) Table 39. Asia Pacific Pulmonary Embolism Drug Revenue by Region (2024-2029) & (US$ Million) Table 40. Latin America Pulmonary Embolism Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 41. Latin America Pulmonary Embolism Drug Sales by Country (2018-2023) & (K Pcs) Table 42. Latin America Pulmonary Embolism Drug Sales by Country (2024-2029) & (K Pcs) Table 43. Latin America Pulmonary Embolism Drug Revenue by Country (2018-2023) & (US$ Million) Table 44. Latin America Pulmonary Embolism Drug Revenue by Country (2024-2029) & (US$ Million) Table 45. Middle East & Africa Pulmonary Embolism Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 46. Middle East & Africa Pulmonary Embolism Drug Sales by Country (2018-2023) & (K Pcs) Table 47. Middle East & Africa Pulmonary Embolism Drug Sales by Country (2024-2029) & (K Pcs) Table 48. Middle East & Africa Pulmonary Embolism Drug Revenue by Country (2018-2023) & (US$ Million) Table 49. Middle East & Africa Pulmonary Embolism Drug Revenue by Country (2024-2029) & (US$ Million) Table 50. Global Pulmonary Embolism Drug Sales (K Pcs) by Type (2018-2023) Table 51. Global Pulmonary Embolism Drug Sales (K Pcs) by Type (2024-2029) Table 52. Global Pulmonary Embolism Drug Sales Market Share by Type (2018-2023) Table 53. Global Pulmonary Embolism Drug Sales Market Share by Type (2024-2029) Table 54. Global Pulmonary Embolism Drug Revenue (US$ Million) by Type (2018-2023) Table 55. Global Pulmonary Embolism Drug Revenue (US$ Million) by Type (2024-2029) Table 56. Global Pulmonary Embolism Drug Revenue Market Share by Type (2018-2023) Table 57. Global Pulmonary Embolism Drug Revenue Market Share by Type (2024-2029) Table 58. Global Pulmonary Embolism Drug Price (USD/Pcs) by Type (2018-2023) Table 59. Global Pulmonary Embolism Drug Price (USD/Pcs) by Type (2024-2029) Table 60. Global Pulmonary Embolism Drug Sales (K Pcs) by Application (2018-2023) Table 61. Global Pulmonary Embolism Drug Sales (K Pcs) by Application (2024-2029) Table 62. Global Pulmonary Embolism Drug Sales Market Share by Application (2018-2023) Table 63. Global Pulmonary Embolism Drug Sales Market Share by Application (2024-2029) Table 64. Global Pulmonary Embolism Drug Revenue (US$ Million) by Application (2018-2023) Table 65. Global Pulmonary Embolism Drug Revenue (US$ Million) by Application (2024-2029) Table 66. Global Pulmonary Embolism Drug Revenue Market Share by Application (2018-2023) Table 67. Global Pulmonary Embolism Drug Revenue Market Share by Application (2024-2029) Table 68. Global Pulmonary Embolism Drug Price (USD/Pcs) by Application (2018-2023) Table 69. Global Pulmonary Embolism Drug Price (USD/Pcs) by Application (2024-2029) Table 70. Accu-Break Pharmaceuticals, Inc. Corporation Information Table 71. Accu-Break Pharmaceuticals, Inc. Description and Business Overview Table 72. Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 73. Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Product Table 74. Accu-Break Pharmaceuticals, Inc. Recent Developments/Updates Table 75. Dong-A Socio Holdings Co. Ltd. Corporation Information Table 76. Dong-A Socio Holdings Co. Ltd. Description and Business Overview Table 77. Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 78. Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Product Table 79. Dong-A Socio Holdings Co. Ltd. Recent Developments/Updates Table 80. F. Hoffmann-La Roche Ltd. Corporation Information Table 81. F. Hoffmann-La Roche Ltd. Description and Business Overview Table 82. F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 83. F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Product Table 84. F. Hoffmann-La Roche Ltd. Recent Developments/Updates Table 85. Genentech, Inc. Corporation Information Table 86. Genentech, Inc. Description and Business Overview Table 87. Genentech, Inc. Pulmonary Embolism Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 88. Genentech, Inc. Pulmonary Embolism Drug Product Table 89. Genentech, Inc. Recent Developments/Updates Table 90. Verseon Corp Corporation Information Table 91. Verseon Corp Description and Business Overview Table 92. Verseon Corp Pulmonary Embolism Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 93. Verseon Corp Pulmonary Embolism Drug Product Table 94. Verseon Corp Recent Developments/Updates Table 95. Key Raw Materials Lists Table 96. Raw Materials Key Suppliers Lists Table 97. Pulmonary Embolism Drug Distributors List Table 98. Pulmonary Embolism Drug Customers List Table 99. Pulmonary Embolism Drug Market Trends Table 100. Pulmonary Embolism Drug Market Drivers Table 101. Pulmonary Embolism Drug Market Challenges Table 102. Pulmonary Embolism Drug Market Restraints Table 103. Research Programs/Design for This Report Table 104. Key Data Information from Secondary Sources Table 105. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Pulmonary Embolism Drug Figure 2. Global Pulmonary Embolism Drug Market Value Comparison by Type (2023-2029) & (US$ Million) Figure 3. Global Pulmonary Embolism Drug Market Share by Type in 2022 & 2029 Figure 4. DS-9231 Product Picture Figure 5. DS-1040 Product Picture Figure 6. TRX-1 Product Picture Figure 7. Others Product Picture Figure 8. Global Pulmonary Embolism Drug Market Value Comparison by Application (2023-2029) & (US$ Million) Figure 9. Global Pulmonary Embolism Drug Market Share by Application in 2022 & 2029 Figure 10. Hospital Figure 11. Clinic Figure 12. Others Figure 13. Global Pulmonary Embolism Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029 Figure 14. Global Pulmonary Embolism Drug Market Size (2018-2029) & (US$ Million) Figure 15. Global Pulmonary Embolism Drug Sales (2018-2029) & (K Pcs) Figure 16. Global Pulmonary Embolism Drug Average Price (USD/Pcs) & (2018-2029) Figure 17. Pulmonary Embolism Drug Report Years Considered Figure 18. Pulmonary Embolism Drug Sales Share by Manufacturers in 2022 Figure 19. Global Pulmonary Embolism Drug Revenue Share by Manufacturers in 2022 Figure 20. The Global 5 and 10 Largest Pulmonary Embolism Drug Players: Market Share by Revenue in 2022 Figure 21. Pulmonary Embolism Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022 Figure 22. Global Pulmonary Embolism Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029 Figure 23. North America Pulmonary Embolism Drug Sales Market Share by Country (2018-2029) Figure 24. North America Pulmonary Embolism Drug Revenue Market Share by Country (2018-2029) Figure 25. U.S. Pulmonary Embolism Drug Revenue Growth Rate (2018-2029) & (US$ Million) Figure 26. Canada Pulmonary Embolism Drug Revenue Growth Rate (2018-2029) & (US$ Million) Figure 27. Europe Pulmonary Embolism Drug Sales Market Share by Country (2018-2029) Figure 28. Europe Pulmonary Embolism Drug Revenue Market Share by Country (2018-2029) Figure 29. Germany Pulmonary Embolism Drug Revenue Growth Rate (2018-2029) & (US$ Million) Figure 30. France Pulmonary Embolism Drug Revenue Growth Rate (2018-2029) & (US$ Million) Figure 31. U.K. Pulmonary Embolism Drug Revenue Growth Rate (2018-2029) & (US$ Million) Figure 32. Italy Pulmonary Embolism Drug Revenue Growth Rate (2018-2029) & (US$ Million) Figure 33. Russia Pulmonary Embolism Drug Revenue Growth Rate (2018-2029) & (US$ Million) Figure 34. Asia Pacific Pulmonary Embolism Drug Sales Market Share by Region (2018-2029) Figure 35. Asia Pacific Pulmonary Embolism Drug Revenue Market Share by Region (2018-2029) Figure 36. China Pulmonary Embolism Drug Revenue Growth Rate (2018-2029) & (US$ Million) Figure 37. Japan Pulmonary Embolism Drug Revenue Growth Rate (2018-2029) & (US$ Million) Figure 38. South Korea Pulmonary Embolism Drug Revenue Growth Rate (2018-2029) & (US$ Million) Figure 39. India Pulmonary Embolism Drug Revenue Growth Rate (2018-2029) & (US$ Million) Figure 40. Australia Pulmonary Embolism Drug Revenue Growth Rate (2018-2029) & (US$ Million) Figure 41. Taiwan Pulmonary Embolism Drug Revenue Growth Rate (2018-2029) & (US$ Million) Figure 42. Indonesia Pulmonary Embolism Drug Revenue Growth Rate (2018-2029) & (US$ Million) Figure 43. Thailand Pulmonary Embolism Drug Revenue Growth Rate (2018-2029) & (US$ Million) Figure 44. Malaysia Pulmonary Embolism Drug Revenue Growth Rate (2018-2029) & (US$ Million) Figure 45. Philippines Pulmonary Embolism Drug Revenue Growth Rate (2018-2029) & (US$ Million) Figure 46. Latin America Pulmonary Embolism Drug Sales Market Share by Country (2018-2029) Figure 47. Latin America Pulmonary Embolism Drug Revenue Market Share by Country (2018-2029) Figure 48. Mexico Pulmonary Embolism Drug Revenue Growth Rate (2018-2029) & (US$ Million) Figure 49. Brazil Pulmonary Embolism Drug Revenue Growth Rate (2018-2029) & (US$ Million) Figure 50. Argentina Pulmonary Embolism Drug Revenue Growth Rate (2018-2029) & (US$ Million) Figure 51. Middle East & Africa Pulmonary Embolism Drug Sales Market Share by Country (2018-2029) Figure 52. Middle East & Africa Pulmonary Embolism Drug Revenue Market Share by Country (2018-2029) Figure 53. Turkey Pulmonary Embolism Drug Revenue Growth Rate (2018-2029) & (US$ Million) Figure 54. Saudi Arabia Pulmonary Embolism Drug Revenue Growth Rate (2018-2029) & (US$ Million) Figure 55. U.A.E Pulmonary Embolism Drug Revenue Growth Rate (2018-2029) & (US$ Million) Figure 56. Global Sales Market Share of Pulmonary Embolism Drug by Type (2018-2029) Figure 57. Global Revenue Market Share of Pulmonary Embolism Drug by Type (2018-2029) Figure 58. Global Pulmonary Embolism Drug Price (USD/Pcs) by Type (2018-2029) Figure 59. Global Sales Market Share of Pulmonary Embolism Drug by Application (2018-2029) Figure 60. Global Revenue Market Share of Pulmonary Embolism Drug by Application (2018-2029) Figure 61. Global Pulmonary Embolism Drug Price (USD/Pcs) by Application (2018-2029) Figure 62. Pulmonary Embolism Drug Value Chain Figure 63. Pulmonary Embolism Drug Production Process Figure 64. Channels of Distribution (Direct Vs Distribution) Figure 65. Distributors Profiles Figure 66. Bottom-up and Top-down Approaches for This Report Figure 67. Data Triangulation Figure 68. Key Executives Interviewed

Accu-Break Pharmaceuticals, Inc. Dong-A Socio Holdings Co. Ltd. F. Hoffmann-La Roche Ltd. Genentech, Inc. Verseon Corp